Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens

To improve virological suppression and address the emerging threat of HIV drug resistance, many low-income and middle-income countries are moving away from non-nucleoside reverse transcriptase inhibitors (NNRTI) and transitioning to dolutegravir as part of a more affordable and standardised antiretr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet infectious diseases 2019-07, Vol.19 (7), p.e246-e252
Hauptverfasser:	Inzaule, Seth C, Hamers, Raph L, Doherty, Meg, Shafer, Robert W, Bertagnolio, Silvia, Rinke de Wit, Tobias F
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Birth control Developing Countries Drug dosages Drug resistance Drug Resistance, Viral - drug effects Female Heterocyclic Compounds, 3-Ring - therapeutic use HIV HIV Infections - drug therapy HIV Integrase Inhibitors - therapeutic use Human immunodeficiency virus Humans Income Infectious diseases Inhibitors Load tests Low income groups Male Mortality Mutation Non-nucleoside reverse transcriptase inhibitors Nucleosides Oxazines Patients Piperazines Public health Pyridones RNA-directed DNA polymerase Switching
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!